BioWorld MedTech

April 14, 2014

New Boston Sci registry to evaluate Vercise DBS in Parkinson's patients

Boston Scientific (Natick, Massachusetts) has enrolled the first patient in a new registry to evaluate clinical outcomes and the economic value of the Vercise deep brain stimulation (DBS) system in patients with Parkinson's disease. Read More

Report from Israel: Nazareth incubator NGT3 raising funds with lofty dual agenda

Washington Roundup: FDA nod to Block HF adds 800K to market for biventricular pacing

MDD's Stock Watch

Report from Europe: Focus shifts from sales to costs for French startups

Court Report: Varian settles patent litigation with University of Pittsburgh for $35M

Deals Roundup: Covidien in plan to acquire New Wave Surgical for $100M

Report from Europe: Seno awarded CE mark for Imagio imaging system

Financings roundup: Ventas prices public offering of senior notes

Sebelius out at HHS, but Burwell unlikely to steer different course

People in Places

Briefly Noted

Product briefs

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for April 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 11, 2025.

FDA clears Dexcom G7 15 Day

BioWorld MedTech

The battle to claim the continuous glucose monitor with the longest wear time continues with Dexcom Inc.’s G7 15 Day continuous glucose monitor gaining U.S. FDA...

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...